Specialty & Hospital Products

Glenmark is proud to supply the NHS with an extensive range of Generics and Branded Generics on Commercial Medicines Units (CMU) Framework agreements. All NHS purchasing points party to CMU Framework agreements can purchase contracted lines via AAH, Mawdsleys, Alliance and Phoenix.

We also support patients with prescription medicines for a range of conditions including:

DERMATOLOGY

Acne

Acne vulgaris is a very common inflammatory disease of the skin.<sup>1,2</sup> Fluctuating hormone (androgen) levels can cause excess sebum production in the skin which has been shown to be a necessary, early step in acne development.<sup>3</sup>

REPSIRATORY

Allergic rhinitis (AR)

AR is an inflammatory disorder of the immune system that occurs when the nasal mucosa becomes exposed and sensitised to allergens such as pollen, dust mites or moulds, triggering the release of histamine.<sup>4,5</sup>

Asthma

Asthma is a chronic lung condition where the bronchial tubes (the channels that help air enter and leave the lungs) become inflamed and obstructed.<sup>6</sup>

Chronic obstructive pulmonary disease (COPD) 

COPD refers to a group of progressive lung conditions where airflow is limited in the lungs including emphysema (a condition where the air sacs in the lungs are damaged) and chronic bronchitis (long term inflammation of the airways).<sup>7</sup>

PAIN

Patients who are already taking strong pain-relieving medicine (opioids) for their persistent cancer pain, can require treatment for their breakthrough pain.<sup>8</sup>

For ordering enquiries relating to any of our products please contact orders.uk@glenmarkpharma.com

For product enquiries please contact medical_information@glenmarkpharma.com

Educational Risk Minimisation Materials
Educational risk minimisation materials for our products can be found HERE
If you would like to report an adverse event, please click here.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Suspected adverse reactions can be reported via the Yellow Card Scheme at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Glenmark can also be contacted to report suspected adverse reactions on 0800 458 0383 or at medical_information@glenmarkpharma.com.

References: 1. Purdy S, DeBerker D. BMJ Clin Evid. 2008;1714. 2. Zouboulis CC, Bettoli V. Br J Dermatol. 2015;Suppl 1:27-36. 3. Del Rosso JQ, Kircik L. J Dermatolog Treat. 2024;35(1):2298878. 4. NICE CKS. Allergic rhinitis: What is it? Available at: https://cks.nice.org.uk/topics/allergic-rhinitis/background-information/definition/. Accessed April 2026. 5. Scadding GK, et al. Clin Exp Allergy 2017;47:856–889. 6. NHS Health A-Z. Asthma. Available at: https://www.nhs.uk/conditions/asthma. Accessed April 2026. 7. NHS Health A to Z. COPD. Available at: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/. Accessed April 2026. 8. Zeppetella G and Davies A N 2013. Available at:
https://doi.org/10.1002/14651858.CD004311.pub3. Accessed April 2026.